In terms of tumor biological behavior, a notable difference between the two studies is the percentage of intermediate tumors harboring a strong PSMA expression (59.7% in our study vs. 2.03%), owing predominantly to the inclusion of giant cell tumor of bone with a frequency of 66.7% in our cohort [24]. The gene discussed is FOLH1; the disease is giant cell tumor.